Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its ...

In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...

A University of Alberta research team has found a genetic variant that can be used to identify which patients with pulmonary arterial hypertension need the most urgent care. "This could potentially ...

In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...

Scientists have created a new "molecular map" uncovering how an important human receptor involved in blood clotting and ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing ...

The trial will enrol up to 30 PAH and ten ILD-PH class II and III patients for ROC-101 combination therapy.

Scientists have created a new “molecular map” uncovering how an important human receptor involved in blood clotting and inflammation works—an advance that could help us design better drugs for ...

An important part of managing pulmonary arterial hypertension is working with a specialist who understands this rare and ...

In this article, we will look at the 8 Most Oversold Penny Stocks to Buy Right Now. After a long stretch when leadership was concentrated in a narrow set of winners, investors have begun paying more ...

Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in New Orleans, March 28 to 30. The ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies ...